TdT+/nonlymphoid antigen+ acute leukemias: Immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential stem cell

Elisabeth M. Paietta, Rasim A. Gucalp, P. Papenhausen, J. P. Dutcher, P. H. Wiernik

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Immunophenotype and karyotype were monitored in 19 adult acute leukemia patients with blast cell populations expressing terminal transferase (TdT) and nonlymphoid antigens either at presentation or at relapse. Three patterns of immunophenotypic course were observed when following the patients through at least one, sometimes two (six patients), or three relapses (one patient). Induction chemotherapy induced predominantly TdT+ leukemias with a minor monoblastic component to become TdT-negative, purely monoblastic without clinical response or change in karyotype in five patients (group 1). In group 2, relapse was associated with the disappearance (four patients) or the appearance of TdT+/nonlymphoid antigen+ features (four patients). In two instances, new nonrandom cytogenetic abnormalities, in one case, evolution of an initial abnormal cytogenetic clone, were found at relapse. Six patients (group 3) presented and relapsed with identical TdT+ myeloblastic, promyeloblastic, or monoblastic immunophenotype and karyotype. In general, FAB classification did not reflect expression of TdT in nonlymphocytic leukemias or the presence of nonlymphoid blast features in lymphocytic leukemias. Lymphoid-specific antigens in addition to TdT were not detected in any of the cases at the time of nonlymphoid antigen expression. In 11 of the 19 patients, simultaneous expression of TdT and myeloid or monocytic antigens could be demonstrated at the single cell level using double-fluorescence staining. These follow-up data are best consistent with a drug-induced maturation drive of a TdT+/monocytic (majority of cases) or TdT+/myelocytic leukemic stem cell with its differentiation commitment being influenced by chemotherapy or by other as yet undefined conditions predisposing to proliferation of the leukemic cell at relapse.

Original languageEnglish (US)
Pages (from-to)485-491
Number of pages7
JournalLeukemia
Volume3
Issue number7
StatePublished - 1989

Fingerprint

Immunologic Monitoring
Leukemia
Stem Cells
Antigens
Recurrence
Karyotype
Therapeutics
Lymphoid Leukemia
Induction Chemotherapy
Transferases
Cytogenetics
Chromosome Aberrations
Clone Cells
Fluorescence
Cell Proliferation
Staining and Labeling
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

TdT+/nonlymphoid antigen+ acute leukemias : Immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential stem cell. / Paietta, Elisabeth M.; Gucalp, Rasim A.; Papenhausen, P.; Dutcher, J. P.; Wiernik, P. H.

In: Leukemia, Vol. 3, No. 7, 1989, p. 485-491.

Research output: Contribution to journalArticle

@article{bfef04180538456a939cd6dc7a6ff3a8,
title = "TdT+/nonlymphoid antigen+ acute leukemias: Immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential stem cell",
abstract = "Immunophenotype and karyotype were monitored in 19 adult acute leukemia patients with blast cell populations expressing terminal transferase (TdT) and nonlymphoid antigens either at presentation or at relapse. Three patterns of immunophenotypic course were observed when following the patients through at least one, sometimes two (six patients), or three relapses (one patient). Induction chemotherapy induced predominantly TdT+ leukemias with a minor monoblastic component to become TdT-negative, purely monoblastic without clinical response or change in karyotype in five patients (group 1). In group 2, relapse was associated with the disappearance (four patients) or the appearance of TdT+/nonlymphoid antigen+ features (four patients). In two instances, new nonrandom cytogenetic abnormalities, in one case, evolution of an initial abnormal cytogenetic clone, were found at relapse. Six patients (group 3) presented and relapsed with identical TdT+ myeloblastic, promyeloblastic, or monoblastic immunophenotype and karyotype. In general, FAB classification did not reflect expression of TdT in nonlymphocytic leukemias or the presence of nonlymphoid blast features in lymphocytic leukemias. Lymphoid-specific antigens in addition to TdT were not detected in any of the cases at the time of nonlymphoid antigen expression. In 11 of the 19 patients, simultaneous expression of TdT and myeloid or monocytic antigens could be demonstrated at the single cell level using double-fluorescence staining. These follow-up data are best consistent with a drug-induced maturation drive of a TdT+/monocytic (majority of cases) or TdT+/myelocytic leukemic stem cell with its differentiation commitment being influenced by chemotherapy or by other as yet undefined conditions predisposing to proliferation of the leukemic cell at relapse.",
author = "Paietta, {Elisabeth M.} and Gucalp, {Rasim A.} and P. Papenhausen and Dutcher, {J. P.} and Wiernik, {P. H.}",
year = "1989",
language = "English (US)",
volume = "3",
pages = "485--491",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - TdT+/nonlymphoid antigen+ acute leukemias

T2 - Immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential stem cell

AU - Paietta, Elisabeth M.

AU - Gucalp, Rasim A.

AU - Papenhausen, P.

AU - Dutcher, J. P.

AU - Wiernik, P. H.

PY - 1989

Y1 - 1989

N2 - Immunophenotype and karyotype were monitored in 19 adult acute leukemia patients with blast cell populations expressing terminal transferase (TdT) and nonlymphoid antigens either at presentation or at relapse. Three patterns of immunophenotypic course were observed when following the patients through at least one, sometimes two (six patients), or three relapses (one patient). Induction chemotherapy induced predominantly TdT+ leukemias with a minor monoblastic component to become TdT-negative, purely monoblastic without clinical response or change in karyotype in five patients (group 1). In group 2, relapse was associated with the disappearance (four patients) or the appearance of TdT+/nonlymphoid antigen+ features (four patients). In two instances, new nonrandom cytogenetic abnormalities, in one case, evolution of an initial abnormal cytogenetic clone, were found at relapse. Six patients (group 3) presented and relapsed with identical TdT+ myeloblastic, promyeloblastic, or monoblastic immunophenotype and karyotype. In general, FAB classification did not reflect expression of TdT in nonlymphocytic leukemias or the presence of nonlymphoid blast features in lymphocytic leukemias. Lymphoid-specific antigens in addition to TdT were not detected in any of the cases at the time of nonlymphoid antigen expression. In 11 of the 19 patients, simultaneous expression of TdT and myeloid or monocytic antigens could be demonstrated at the single cell level using double-fluorescence staining. These follow-up data are best consistent with a drug-induced maturation drive of a TdT+/monocytic (majority of cases) or TdT+/myelocytic leukemic stem cell with its differentiation commitment being influenced by chemotherapy or by other as yet undefined conditions predisposing to proliferation of the leukemic cell at relapse.

AB - Immunophenotype and karyotype were monitored in 19 adult acute leukemia patients with blast cell populations expressing terminal transferase (TdT) and nonlymphoid antigens either at presentation or at relapse. Three patterns of immunophenotypic course were observed when following the patients through at least one, sometimes two (six patients), or three relapses (one patient). Induction chemotherapy induced predominantly TdT+ leukemias with a minor monoblastic component to become TdT-negative, purely monoblastic without clinical response or change in karyotype in five patients (group 1). In group 2, relapse was associated with the disappearance (four patients) or the appearance of TdT+/nonlymphoid antigen+ features (four patients). In two instances, new nonrandom cytogenetic abnormalities, in one case, evolution of an initial abnormal cytogenetic clone, were found at relapse. Six patients (group 3) presented and relapsed with identical TdT+ myeloblastic, promyeloblastic, or monoblastic immunophenotype and karyotype. In general, FAB classification did not reflect expression of TdT in nonlymphocytic leukemias or the presence of nonlymphoid blast features in lymphocytic leukemias. Lymphoid-specific antigens in addition to TdT were not detected in any of the cases at the time of nonlymphoid antigen expression. In 11 of the 19 patients, simultaneous expression of TdT and myeloid or monocytic antigens could be demonstrated at the single cell level using double-fluorescence staining. These follow-up data are best consistent with a drug-induced maturation drive of a TdT+/monocytic (majority of cases) or TdT+/myelocytic leukemic stem cell with its differentiation commitment being influenced by chemotherapy or by other as yet undefined conditions predisposing to proliferation of the leukemic cell at relapse.

UR - http://www.scopus.com/inward/record.url?scp=0024356610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024356610&partnerID=8YFLogxK

M3 - Article

C2 - 2733453

AN - SCOPUS:0024356610

VL - 3

SP - 485

EP - 491

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -